Physician profile
Donald E Krouse
NPI 1710977079
$425.62
in general payments reported to CMS, 2019-2025
14 companies · $70.04 in 2025
The $70.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.80 · 2021: $61.29 · 2022: $57.29 · 2023: $115 · 2024: $103 · 2025: $70.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.43 | 2023 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $64.73 | 2021-2023 | Farxiga |
| Abbvie INC. | $48.04 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $45.51 | 2024 | Iovera |
| Exact Sciences Corporation | $38.51 | 2024-2025 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $21.42 | 2024 | Crysvita |
| Gilead Sciences, INC. | $21.13 | 2023 | |
| Vanda Pharmaceuticals INC. | $20.47 | 2025 | Fanapt |
| Lilly USA, LLC | $18.97 | 2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.50 | 2021 | |
| Novo Nordisk INC | $15.21 | 2021 | |
| Indivior INC. | $14.53 | 2023 | Sublocade |
| Glaxosmithkline, LLC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Krouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.